Use of hormonal contraception — regardless of type or delivery method — was not associated with a significant increased risk for idiopathic intracranial hypertension (IIH) in women of reproductive age, a new study showed.
The systematic review and meta-analysis is the first to show no link between IIH prevalence and the use of hormonal birth control, including oral contraceptives, intrauterine devices (IUDs), hormonal injections, or implants.
“The findings of this study provide reassurance to the treating physicians that hormonal contraception need not be considered a contraindication in IIH,” investigator Arun N.E. Sundaram, MD, Division of Neurology, University of Toronto, Ontario, Canada, told Medscape Medical News.
The study was published online on March 25 in Neurology.
‘Longstanding Concern’
Early case reports and small observational studies have suggested a possible temporal relationship between the start of hormonal contraception among women of reproductive age and subsequent IIH diagnosis, including reports involving oral contraceptive pills and IUDs.
“The use of hormonal contraception in patients with IIH has been controversial and a longstanding concern,” Sundaram said.
“Patients with IIH have been receiving conflicting information from physicians regarding the use of hormones, but most of the available literature did not largely support hormonal contraception as a substantial risk factor in IIH,” he added.
To investigate further, researchers conducted a systematic review of observational that compared hormonal contraceptive use among women with and without IIH. The final analysis included 10 case-control studies and three cohort studies with 5351 women with IIH and 669,260 control participants (mean age, 33.3 years).
Hormonal contraceptives included oral contraceptive pills, IUDs, vaginal rings, injectable agents such as medroxyprogesterone acetate, subdermal implants, and transdermal patches.
What the Numbers Revealed?
The use of any hormonal contraception was reported by 25.2% of the IIH group vs 19.2% of the control group.
The risk for IIH was not statistically different between groups (odds ratio, 0.93; P = .60). Subgroup analyses by contraception type also showed no significant associations.
Results were consistent across multiple sensitivity analyses, including those restricted to more recent studies and those using standardized IIH diagnostic criteria.
Nine of the included studies found no significant association between hormonal contraception use and IIH prevalence; three found lower odds of hormonal contraception use among individuals with IIH than among control individuals; and one found higher odds, specifically for the levonorgestrel IUD. However, this single finding did not persist in the meta-analysis, which found no association between IUD use and IIH prevalence across five studies.
Study limitations included low to very low certainty of evidence and considerable heterogeneity across studies, compounded by incomplete data on important factors such as obesity and variability in how contraceptive exposure was defined.
Reassuring Findings
The current findings should reassure patients and clinicians about the low risk for oral contraceptives and IUDs among women with IIH, Andrew G. Lee, MD, a neuro-ophthalmologist and professor of neurology, neurosurgery, and ophthalmology at Weill Cornell Medical College in New York City, told Medscape Medical News.
The role of hormonal contraception in IIH has been overestimated in clinical practice, Lee said, likely due to clinician bias.
“Doctors have a bias and one of their biases is they like to blame something and have a diagnosis. We hate that diagnosis ‘idiopathic.’ However, IIH remains idiopathic to this day,” said Lee, who was not part of the study.
The results also highlight the need to check for other causes when IIH is suspected, Lee said. The only scenario in which hormonal therapy may be causal is if a patient has a cerebral venous sinus thrombosis (CVST) diagnosis, a rare clot that can mimic or cause increased intracranial pressure.
Estrogen-containing hormonal contraception is a known risk factor for CVST, which is distinct from IIH, said Lee, who also is chair of ophthalmology at Blanton Eye Institute, Houston Methodist Hospital, Houston.
“Patients with suspected IIH should have an MRI and a [magnetic resonance] venogram to exclude venous sinus thrombosis,” Lee suggested.
Future research should explore prothrombotic conditions that could increase susceptibility to IIH in the context of hormonal contraception, he added.
“The bottom line is that given the limited quality of available evidence and considerable heterogeneity in the existing studies, future large-scale, well-designed studies, particularly in diverse patient populations will be necessary to validate these findings,” he said.
Sundaram and Lee reported having no relevant financial relationships.
Facts Only
A systematic review and meta-analysis found no significant link between hormonal contraception use and idiopathic intracranial hypertension (IIH) in women of reproductive age.
The study was led by Arun N.E. Sundaram, MD, of the University of Toronto, and published in *Neurology* on March 25.
The analysis included 10 case-control studies and three cohort studies, totaling 5,351 women with IIH and 669,260 control participants.
Hormonal contraceptives examined included oral pills, IUDs, vaginal rings, injections, implants, and transdermal patches.
25.2% of women with IIH reported using hormonal contraception, compared to 19.2% of controls.
The overall odds ratio for IIH risk with hormonal contraception was 0.93 (P = .60), indicating no statistically significant association.
Subgroup analyses by contraceptive type also showed no significant links.
One study suggested higher odds of IIH with levonorgestrel IUDs, but this finding did not persist in the meta-analysis.
Study limitations included low to very low certainty of evidence and heterogeneity in diagnostic criteria and contraceptive exposure definitions.
Andrew G. Lee, MD, a neuro-ophthalmologist, noted that hormonal contraception’s role in IIH may have been overestimated due to clinician bias.
Lee emphasized the importance of ruling out cerebral venous sinus thrombosis (CVST) in suspected IIH cases, as estrogen-containing contraceptives are a known risk factor for CVST.
The study authors and commentators reported no relevant financial conflicts of interest.
Executive Summary
Full Take
**Steelman:** This study provides robust evidence challenging long-held concerns about hormonal contraception as a risk factor for IIH. By synthesizing data from over 5,000 cases and 669,000 controls, it offers a more definitive answer than prior small-scale or observational studies. The inclusion of multiple contraceptive types and sensitivity analyses strengthens its conclusions. The authors and independent experts like Dr. Lee acknowledge the study’s limitations but frame it as a step toward clarifying a contentious clinical issue.
**Pattern Scan:** The narrative here is relatively clean, but a few subtle patterns merit attention. The framing of "longstanding concern" and "controversial" (ARC-0024 Ambiguity) could imply a more divided scientific consensus than actually exists, given that most prior literature did not strongly support the link. The emphasis on reassurance (ARC-0031 Emotional Appeal) may subtly nudge clinicians toward dismissing hormonal contraception as a factor, even as the study itself calls for more research. The distinction between IIH and CVST is critical but could be overlooked in broader discussions, risking oversimplification (ARC-0012 False Equivalence).
**Root Cause:** The paradigm here reflects a broader tension in medicine between anecdotal clinical observations and large-scale evidence. Early case reports created a plausible but unproven narrative that hormonal contraception might trigger IIH, leading to cautious or conflicting advice. This study disrupts that narrative by prioritizing meta-analytic rigor over clinical intuition. The underlying assumption—that hormonal influences *must* play a role in IIH because it predominantly affects women of reproductive age—goes unchallenged, even as the data fails to support it.
**Implications:** For patients, this study could reduce unnecessary anxiety about contraceptive choices, but it also risks downplaying individual variability. For clinicians, it may shift focus toward other IIH risk factors, like obesity, but the call for MRI/venograms to rule out CVST adds complexity. The second-order consequence is a potential overcorrection: if hormonal contraception is deemed "safe," other prothrombotic or metabolic interactions might be overlooked in IIH management.
**Bridge Questions:** What biological mechanisms *could* link hormonal contraception to IIH, even if population-level data doesn’t show it? How might obesity—a known IIH risk factor—confound these findings, given its underreporting in studies? If hormonal contraception isn’t a major driver, what other environmental or genetic factors warrant investigation?
**Counterstrike Scan:** A coordinated influence campaign might exploit this study to dismiss all concerns about hormonal contraception’s neurological effects, using the meta-analysis as a cudgel to silence dissenting clinical observations. However, the actual content resists this: it acknowledges limitations, highlights the need for further research, and distinguishes IIH from CVST. No structural alignment with manipulation is detected.
**Patterns detected:** ARC-0024 Ambiguity, ARC-0031 Emotional Appeal, ARC-0012 False Equivalence
Sentinel — Human
This text is likely to be human-written. It demonstrates variety in sentence length and lacks overuse of hedging phrases. The text also has a personal voice and presents a balanced view, indicating human journalism.